Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
Neuropsychological Effects of Brain Autograft of Adrenal Medullary Tissue for Treatment of Parkinson's Disease
Neurol 38:1442-1450, Ostrosky-Solis,F.,et al, 1988
Update on Parkinson Disease
NY State J Med, 87:147-1531987., Lieberman,A.N., 1987
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Changing Gears - DBS for Dopaminergic Desensitization in Parkinsons Disease?
Ann Neurol 90:699-710, Weiss, D.,et al, 2021
A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson's Disease
NEJM 346:1174-1175, Restivo,D.A.,et al, 2002
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Multiple System Atrophy presenting as Parkinsonism:Clinical Features and Diagnostic Criteria
JNNP 59:144-151, Albanese,A.,et al, 1995
Clozapine is Beneficial for Psychosis in Parkinson's Disease
NEurol 41:1699-1700, Kahn,N.,et al, 1991
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
Treatment of Dopaminomimetic Psychosis in Parkinson's Disease with Electroconvulsive Therapy
Can J Neurol Sci 15:32-34, Hurwitz,T.A.&Waterman,C., 1988